Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

Stopped early · Phase 2

Conditions studied: Acute Myeloid Leukemia

In brief

The purpose of this study is to find out if by giving a combination of 3 drugs the leukemia will go into complete remission (meaning the leukemia is completely gone), and to find out how long it stays away. The drugs used in this project are FDA approved and commercially available.

Key facts

Study ID

NCT02341495

Run by

Elizabeth Henry

People needed

4

Starts

2013-02-01

Expected to finish

2016-11-01

Last updated by the study team

2020-02-27

Who can join

Age: 65 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 65 or older (must have reached 65th birthday)
• Morphologically confirmed diagnosis of AML, excluding AML-M3
• Must have a Zubrod performance status of 0-3

You may not qualify if…

• Patients with known HIV infection are excluded. If HIV infection is suspected based on clinical condition, testing may be performed at the discretion of treatment team, but is not mandated prior to enrollment.
• Patients with central nervous system involvement by AML are excluded
• Patients with history of an active cancer (except basal cell and squamous cell cancers of the skin) within the previous 2 years are excluded

Where it is running

• Loyola University Cardinal Bernardin Cancer Center — Maywood, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.